Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention?

Area of Science:

• Cardiovascular Medicine
• Lipidology
• Metabolic Disorders

Background:

• The "lipid triad" or "atherogenic lipoprotein phenotype" describes dyslipidemia with high triglycerides, low HDL-cholesterol, and small, dense LDL particles.
• This phenotype is prevalent in coronary artery disease patients, potentially exceeding LDL-cholesterol's clinical significance.
• Evidence links therapies targeting HDL-cholesterol and triglycerides to reduced cardiovascular risk.

Purpose of the Study:

• To highlight the clinical importance of the atherogenic lipoprotein phenotype in cardiovascular disease.
• To emphasize the benefits of managing the lipid triad for cardiovascular risk reduction.
• To advocate for broader LDL size measurement in high-risk patients.

Main Methods:

• Review of existing evidence on the lipid triad and cardiovascular risk.
• Analysis of therapeutic effects on HDL-cholesterol, triglycerides, and LDL particle size.
• Consideration of National Cholesterol Education Program guidelines for high-risk patients.

Main Results:

• Therapies targeting HDL-cholesterol and triglycerides significantly reduce cardiovascular risk.
• Hypolipidemic treatments can increase LDL particle size, correlating with coronary stenosis regression.
• The atherogenic lipoprotein phenotype is common in coronary artery disease.

Conclusions:

• Managing the lipid triad components effectively reduces cardiovascular event risk.
• LDL size measurement should be considered for patients at high cardiovascular risk.
• The atherogenic lipoprotein phenotype warrants attention in cardiovascular risk assessment and management.